受容体分解のためのE3ユビキチンリガゼの抗体標的化
Hadir Marei1, Wen-Ting K Tsai2, Yee-Seir Kee2
1Discovery Oncology, Genentech, South San Francisco, CA, USA.
Nature
|September 21, 2022
まとめ
研究者は細胞表面のタンパク質を分解する タンパク質分解標的抗体 (PROTAB) を開発しました この新しい方法は 標的型タンパク質分解の 強力で選択的なアプローチで 伝統的な抑制療法の限界を克服します
科学分野:
- 分子生物学
- 薬物の発見
- 腫瘍学
背景:
- プラズマ膜受容体を標的とする現在の治療法は,しばしばリガンド結合または酵素活性を抑制し,多領域タンパク質構造のためにタンパク質機能を完全に抑制することができない.
- タンパク質分解を標的とするキメラ (PROTACs) が示した標的型タンパク質分解は,抑制よりも利点があるが,経口で生物利用可能な異性生物機能化合物の開発には課題がある.
- 高アフィニティの二重標的結合剤の作成の複雑さは,効果的な治療介入のための新しい戦略を必要とします.
研究 の 目的:
- 細胞表面のタンパク質を分解するための新技術であるタンパク質分解標的抗体 (PROTAB) の開発
- 指3 (ZNRF3) などの特定のタンパク質を標的とするPROTABの有効性を実証する.
- 様々な細胞表面E3ユビキチンリガゼとトランスメブラン受容体におけるオンデマンド分解のためのPROTAB技術の適応性を調査する.
主な方法:
- 細胞表面のE3ユビキチンリガゼとトランスメブランタンパク質を結びつけるためのタンパク質を標的とする抗体 (PROTAB) の開発.
- 大腸がんモデルにおけるZNRF3を中心に,PROTABによる標的分解のインビトロおよびインビボ検証.
- 様々なE3リガゼと受容体の体系的なスクリーニングで,PROTABの汎用性と"オンデマンド"分解能力を評価する.
- 降解効率を最適化し,基礎となる原理を理解するために,抗体形式のエンジニアリング.
主要な成果:
- PROTABsは,インビトロとインビボの両方で,標的タンパク質の分解を成功的に誘導しました.
- このアプローチは,ZNRF3をターゲットにすることで,大腸がん特異的な退廃を達成する効果を示した.
- この技術は,細胞表面のE3リガゼと受容体の範囲で"オンデマンド"の分解に適応できることを証明した.
- 標的の分解に関するルールの洞察は,設計された抗体形式によって得られた.
結論:
- タンパク質分解を標的とする抗体 (PROTABs) は,細胞表面タンパク質の強力で生物利用可能で組織選択的な分解のための有効な戦略です.
- この技術は,標的型タンパク質分解のための新しいパラダイムを提供し,既存の治療方法の限界を克服する可能性があります.
- PROTABは癌を含む様々な病気の新たな治療法を開発するための 柔軟なプラットフォームを提供します
関連する概念動画
Regulated Protein Degradation
7.5K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.5K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
The Proteasome
1.1K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.1K
Export of Misfolded Proteins out of the ER
3.8K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
3.8K
GPCR Desensitization
6.4K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.4K
The Unfolded Protein Response
5.0K
The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
5.0K


